Clinical trials of antiangiogenic drugs: Opportunities, problems, and assessment of initial results

Journal of Clinical Oncology

Volumn 19, Issue 18 SUPPL., 2001, Pages

  Kerbel, R S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; AE 941; ANGIOGENESIS INHIBITOR; ANGIOZYME; APILDINE; APRA; AVICINE; CEP 701; CETUXIMAB; CILENGITIDE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLAVOPIRIDOL; GAMMA INTERFERON; GBC 590; GEFITINIB; IM 8862; IMMTHER; INTERLEUKIN 12; LDI 200; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; OCTREOTIDE; REBIMASTAT; SOLIMASTAT; SQUALAMINE; SURAMIN; TETRATHIOMOLYBDIC ACID; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRALDON;

ADVANCED CANCER; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR REGRESSION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME;

EID: 0035884219     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (76)

1. Tumor angiogenesis: Therapeutic implications
2. Tumor angiogenesis: Past, present, and the near future
3. Genes expressed in human tumor endothelium
4. Anti-angiogenic agents: Clinical trial design and therapies in development
5. Clinical trial designs for cytostatic agents: Are new approaches needed?
6. Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging
7. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
8. ZD1839 ('Iressa') as an anticancer agent
9. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
10. Continuous administration of ZD1889 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
11. Targeting tumor vasculature: The development of combretastatin A4
12. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
13. Survival without tumor shrinkage: Re-evaluation of survival gain by cytostatic effect of chemotherapy
14. Prolonged stable disease effects survival in patients with solid gastric tumor: Analysis of phase II studies of doxifluridine
15. Phase I clinical trial of recombinant human endostatin (rHE) in patients (Pts) with solid tumors: Pharmacokinetic (PK), safety, and efficacy analysis using surrogate endpoints and radiologic response
16. Recombinant human angiostatin (rhA): A phase I clinical trial assessing safety, pharmacokinetics (PK) and pharmacodynamics (PD)
17. Hope in the lab: A special report - A cautious awe greets drugs that eradicate tumors in mice
18. Hype, hope, cancer
19. The power of the front page of The New York Times
20. The epidermal growth factor receptor and its inhibition in cancer therapy
21. Therapeutic application of anti-growth factor receptor antibodies
22. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
23. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for combination therapy
24. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
25. Cancer: Looking outside the genome
26. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
27. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy
28. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
29. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells
30. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas
31. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
32. Role of endothelial cell survival and death signals in angiogenesis
33. Marked induction of the IAP family anti-apoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
34. Heterogeneous vascular dependence of tumor cell populations
35. Angiogenesis research: Guidelines for translation to clinical application
36. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas
37. The onset and extent of genomic instability in sporadic colorectal tumor progression
38. Genetic and biochemical characterization of multidrug resistance
39. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis
40. Cancer research: Why some leukemia cells resist STI-571
41. Clinical resistance to ST1-571 cancer therapy caused by BCR-ABL gene mutation or amplification
42. Interferons a and b down-regulate the expression of basic fibroblast growth factor in human carcinomas
43. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alpha-2a
44. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
45. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
46. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12
47. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
48. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
49. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
50. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
51. TNP-470: An angiogenesis inhibitor in clinical development for cancer
52. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer
53. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma
54. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
55. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer
56. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
57. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: Potential efficacy of the combination and demonstration of pharmacokinetic interaction
58. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study
59. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis
60. Antiangiogenic strategies and agents in clinical trials
61. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor
62. Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats
63. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy
64. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first line chemotherapy: An NC1C-CTG and EORTC study
65. Antitumor activity of thalidomide in refractory multiple myeloma
66. Thalidomide: A revival story
67. Carboplatin (C) + paclitaxel (T) + RhuMAb-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer
68. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
69. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
70. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing C-KIT (CD17)
71. STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study
72. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
73. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
74. Establishing a link between oncogenes and tumor angiogenesis
75. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
76. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome